Glaukos Corp (GKOS)

$119.15

+1.5

(+1.27%)▲

Live

Performance

  • $117.60
    $120.00
    $119.15
    downward going graph

    1.3%

    Downside

    Day's Volatility :2.0%

    Upside

    0.71%

    downward going graph
  • $59.22
    $126.96
    $119.15
    downward going graph

    50.3%

    Downside

    52 Weeks Volatility :53.36%

    Upside

    6.15%

    downward going graph

Returns

PeriodGlaukos CorpSector (Health Care)Index (Russel 2000)
3 Months
18.26%
6.5%
0.0%
6 Months
27.16%
7.1%
0.0%
1 Year
54.88%
9.8%
0.0%
3 Years
145.21%
14.2%
-20.2%

Highlights

Market Capitalization
6.6B
Book Value
$9.04
Earnings Per Share (EPS)
-2.88
PEG Ratio
1.64
Wall Street Target Price
122.82
Profit Margin
-43.16%
Operating Margin TTM
-31.93%
Return On Assets TTM
-7.95%
Return On Equity TTM
-29.37%
Revenue TTM
326.4M
Revenue Per Share TTM
6.68
Quarterly Revenue Growth YOY
15.9%
Gross Profit TTM
213.9M
EBITDA
-87.0M
Diluted Eps TTM
-2.88
Quarterly Earnings Growth YOY
18.96
EPS Estimate Current Year
-2.21
EPS Estimate Next Year
-1.29
EPS Estimate Current Quarter
-0.57
EPS Estimate Next Quarter
-0.5

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Glaukos Corp(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3.08%

Current $119.15
Target $122.82

Company Financials

FY18Y/Y Change
Revenue
181.3M
↑ 13.83%
Net Income
-13.0M
↑ 13977.17%
Net Profit Margin
-7.14%
↓ 7.08%
FY19Y/Y Change
Revenue
237.0M
↑ 30.73%
Net Income
15.4M
↓ 219.1%
Net Profit Margin
6.51%
↑ 13.65%
FY20Y/Y Change
Revenue
225.0M
↓ 5.07%
Net Income
-120.3M
↓ 880.26%
Net Profit Margin
-53.5%
↓ 60.01%
FY21Y/Y Change
Revenue
294.0M
↑ 30.7%
Net Income
-49.6M
↓ 58.79%
Net Profit Margin
-16.87%
↑ 36.63%
FY22Y/Y Change
Revenue
282.9M
↓ 3.79%
Net Income
-99.2M
↑ 100.02%
Net Profit Margin
-35.07%
↓ 18.2%
FY23Y/Y Change
Revenue
314.7M
↑ 11.26%
Net Income
-134.7M
↑ 35.75%
Net Profit Margin
-42.79%
↓ 7.72%
Q4 FY22Q/Q Change
Revenue
71.2M
↓ 0.06%
Net Income
-31.5M
↑ 14.08%
Net Profit Margin
-44.17%
↓ 5.48%
Q1 FY23Q/Q Change
Revenue
73.9M
↑ 3.75%
Net Income
-34.6M
↑ 10.06%
Net Profit Margin
-46.86%
↓ 2.69%
Q2 FY23Q/Q Change
Revenue
80.4M
↑ 8.8%
Net Income
-32.8M
↓ 5.24%
Net Profit Margin
-40.81%
↑ 6.05%
Q3 FY23Q/Q Change
Revenue
78.0M
↓ 2.92%
Net Income
-30.4M
↓ 7.22%
Net Profit Margin
-39.01%
↑ 1.8%
Q4 FY23Q/Q Change
Revenue
82.4M
↑ 5.53%
Net Income
-36.8M
↑ 20.81%
Net Profit Margin
-44.65%
↓ 5.64%
Q1 FY24Q/Q Change
Revenue
85.6M
↑ 3.95%
Net Income
-40.8M
↑ 11.04%
Net Profit Margin
-47.7%
↓ 3.05%
FY18Y/Y Change
Total Assets
207.0M
↑ 24.8%
Total Liabilities
33.1M
↑ 19.82%
FY19Y/Y Change
Total Assets
818.4M
↑ 295.42%
Total Liabilities
145.1M
↑ 338.32%
FY20Y/Y Change
Total Assets
1.0B
↑ 22.86%
Total Liabilities
338.1M
↑ 132.93%
FY21Y/Y Change
Total Assets
1.0B
↑ 4.4%
Total Liabilities
462.5M
↑ 36.83%
FY22Y/Y Change
Total Assets
1.0B
↓ 4.51%
Total Liabilities
472.4M
↑ 2.13%
FY23Y/Y Change
Total Assets
940.4M
↓ 6.18%
Total Liabilities
478.6M
↑ 1.33%
Q4 FY22Q/Q Change
Total Assets
1.0B
↓ 0.6%
Total Liabilities
472.4M
↑ 2.71%
Q1 FY23Q/Q Change
Total Assets
972.6M
↓ 2.97%
Total Liabilities
464.1M
↓ 1.76%
Q2 FY23Q/Q Change
Total Assets
956.7M
↓ 1.63%
Total Liabilities
467.9M
↑ 0.83%
Q3 FY23Q/Q Change
Total Assets
948.6M
↓ 0.85%
Total Liabilities
471.0M
↑ 0.65%
Q4 FY23Q/Q Change
Total Assets
940.4M
↓ 0.87%
Total Liabilities
478.6M
↑ 1.63%
Q1 FY24Q/Q Change
Total Assets
933.3M
↓ 0.75%
Total Liabilities
482.6M
↑ 0.83%
FY18Y/Y Change
Operating Cash Flow
18.9M
↓ 26.05%
Investing Cash Flow
-26.4M
↑ 125.12%
Financing Cash Flow
21.6M
↑ 362.31%
FY19Y/Y Change
Operating Cash Flow
-369.0K
↓ 101.96%
Investing Cash Flow
43.4M
↓ 264.49%
Financing Cash Flow
-9.6M
↓ 144.7%
FY20Y/Y Change
Operating Cash Flow
-23.0M
↑ 6129.81%
Investing Cash Flow
-205.1M
↓ 572.21%
Financing Cash Flow
262.5M
↓ 2822.05%
FY21Y/Y Change
Operating Cash Flow
24.7M
↓ 207.48%
Investing Cash Flow
-58.2M
↓ 71.6%
Financing Cash Flow
39.3M
↓ 85.05%
FY22Y/Y Change
Operating Cash Flow
-33.1M
↓ 233.9%
Investing Cash Flow
44.8M
↓ 176.9%
Financing Cash Flow
6.3M
↓ 84.08%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.1M
↓ 84.4%
Investing Cash Flow
16.7M
↓ 31.72%
Financing Cash Flow
529.0K
↓ 87.42%
Q1 FY23Q/Q Change
Operating Cash Flow
-30.8M
↑ 643.81%
Investing Cash Flow
-13.8M
↓ 183.05%
Financing Cash Flow
1.2M
↑ 117.77%
Q2 FY23Q/Q Change
Operating Cash Flow
-8.2M
↓ 73.47%
Investing Cash Flow
26.0M
↓ 287.62%
Financing Cash Flow
-880.0K
↓ 176.39%
Q3 FY23Q/Q Change
Operating Cash Flow
-8.2M
↑ 0.09%
Investing Cash Flow
14.9M
↓ 42.6%
Financing Cash Flow
7.5M
↓ 948.52%

Technicals Summary

Sell

Neutral

Buy

Glaukos Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Glaukos Corp
Glaukos Corp
0.85%
27.16%
54.88%
145.21%
54.32%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Glaukos Corp
Glaukos Corp
NA
NA
1.64
-2.21
-0.29
-0.08
NA
9.04
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Glaukos Corp
Glaukos Corp
Buy
$6.6B
54.32%
NA
-43.16%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Glaukos Corp

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 78.04M → 85.62M (in $), with an average increase of 4.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -30.44M → -40.83M (in $), with an average decrease of 15.9% per quarter

Institutional Holdings

  • BlackRock Inc

    14.46%

  • FMR Inc

    13.47%

  • Vanguard Group Inc

    9.72%

  • Brown Capital Management, LLC

    3.90%

  • State Street Corporation

    3.34%

  • HHG PLC

    2.95%

Corporate Announcements

  • Glaukos Corp Earnings

    Glaukos Corp’s price-to-earnings ratio stands at None

    Read More

Company Information

glaukos corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. glaukos has pioneered micro-invasive glaucoma surgery, or migs, to revolutionize the traditional glaucoma treatment and management paradigm. the company launched the istent trabecular micro-bypass stent, its first migs device, in the united states in 2012. glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. glaukos believes the istent is the smallest medical device ever approved by the food and drug administration, or fda, measuring 1.0 mm long and 0.33 mm wide. in june 2015, the company completed an initial public offering and its shares are now traded on the new york stock exchange unde

Organization
Glaukos Corp
Employees
907
CEO
Mr. Thomas William Burns
Industry
Health Technology

Discover More

FAQs